EMA Authorised: Sutent (sunitinib) — Pfizer Limited

View source ↗

Summary

Sutent (sunitinib) has been authorised by the EMA with indications for gastrointestinal stromal tumor, renal cell carcinoma, and neuroendocrine tumor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Neuroendocrine Tumor
• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Status: Authorised. Therapeutic area: Gastrointestinal Stromal Tumors;Carcinoma, Renal Cell;Neuroendocrine Tumors. MAH: Pfizer Limited. Decision date: 10/03/2025